Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cerevel Therapeutics Hldg Inc (NQ: CERE )

33.40 +0.83 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cerevel Therapeutics Hldg Inc

< Previous 1 2 3 4 Next >
Analyst Expectations for Cerevel Therapeutics Hldg's Future
 
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
 
Via Benzinga
Analyst Expectations for Cerevel Therapeutics Hldg's Future
 
Via Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
 
Via Benzinga
Cerevel Therapeutics Hldg: Q1 Earnings Insights
 
Via Benzinga
Where Cerevel Therapeutics Hldg Stands With Analysts
 
Via Benzinga
Analyst Expectations for Cerevel Therapeutics Hldg's Future
 
Via Benzinga
Data Shows Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
 
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
 
Via Benzinga
Analyst Ratings for Cerevel Therapeutics Hldg
Analysts have provided the following ratings for Cerevel Therapeutics Hldg (NASDAQ:CERE) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
 
Via Benzinga
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous... 
Via Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
 
Via Benzinga
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%
  B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from $73 to $61. Tyson Foods shares fell 1.9% to $66.44 in pre-market trading. 
Via Benzinga
Why Cerevel Therapeutics Holdings Shares Are Nosediving
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarter EPS results and filed... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
Cerevel Therapeutics Hldg (NASDAQ:CERE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Cerevel Therapeutics Hldg
Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades See all analyst ratings upgrades. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.